294 related articles for article (PubMed ID: 17085666)
1. A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.
Mayer A; Francis RJ; Sharma SK; Tolner B; Springer CJ; Martin J; Boxer GM; Bell J; Green AJ; Hartley JA; Cruickshank C; Wren J; Chester KA; Begent RH
Clin Cancer Res; 2006 Nov; 12(21):6509-16. PubMed ID: 17085666
[TBL] [Abstract][Full Text] [Related]
2. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.
Napier MP; Sharma SK; Springer CJ; Bagshawe KD; Green AJ; Martin J; Stribbling SM; Cushen N; O'Malley D; Begent RH
Clin Cancer Res; 2000 Mar; 6(3):765-72. PubMed ID: 10741695
[TBL] [Abstract][Full Text] [Related]
3. Clearance mechanism of a mannosylated antibody-enzyme fusion protein used in experimental cancer therapy.
Kogelberg H; Tolner B; Sharma SK; Lowdell MW; Qureshi U; Robson M; Hillyer T; Pedley RB; Vervecken W; Contreras R; Begent RH; Chester KA
Glycobiology; 2007 Jan; 17(1):36-45. PubMed ID: 17000699
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
Pedley RB; Sharma SK; Boxer GM; Boden R; Stribbling SM; Davies L; Springer CJ; Begent RH
Cancer Res; 1999 Aug; 59(16):3998-4003. PubMed ID: 10463598
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
Blakey DC; Davies DH; Dowell RI; East SJ; Burke PJ; Sharma SK; Springer CJ; Mauger AB; Melton RG
Br J Cancer; 1995 Nov; 72(5):1083-8. PubMed ID: 7577451
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours.
Francis RJ; Sharma SK; Springer C; Green AJ; Hope-Stone LD; Sena L; Martin J; Adamson KL; Robbins A; Gumbrell L; O'Malley D; Tsiompanou E; Shahbakhti H; Webley S; Hochhauser D; Hilson AJ; Blakey D; Begent RH
Br J Cancer; 2002 Sep; 87(6):600-7. PubMed ID: 12237768
[TBL] [Abstract][Full Text] [Related]
7. ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts.
Blakey DC; Burke PJ; Davies DH; Dowell RI; East SJ; Eckersley KP; Fitton JE; McDaid J; Melton RG; Niculescu-Duvaz IA; Pinder PE; Sharma SK; Wright AF; Springer CJ
Cancer Res; 1996 Jul; 56(14):3287-92. PubMed ID: 8764123
[TBL] [Abstract][Full Text] [Related]
8. Predictive physiologically based pharmacokinetic model for antibody-directed enzyme prodrug therapy.
Fang L; Sun D
Drug Metab Dispos; 2008 Jun; 36(6):1153-65. PubMed ID: 18356268
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft.
Stribbling SM; Martin J; Pedley RB; Boden JA; Sharma SK; Springer CJ
Cancer Chemother Pharmacol; 1997; 40(4):277-84. PubMed ID: 9225945
[TBL] [Abstract][Full Text] [Related]
10. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.
Springer CJ; Niculescu-Duvaz I
Anticancer Drug Des; 1995 Jul; 10(5):361-72. PubMed ID: 7639927
[TBL] [Abstract][Full Text] [Related]
11. Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy.
Sharma SK; Pedley RB; Bhatia J; Boxer GM; El-Emir E; Qureshi U; Tolner B; Lowe H; Michael NP; Minton N; Begent RH; Chester KA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):814-25. PubMed ID: 15701872
[TBL] [Abstract][Full Text] [Related]
12. Radiolabelling of glycosylated MFE-23::CPG2 fusion protein (MFECP1) with 99mTc for quantitation of tumour antibody-enzyme localisation in antibody-directed enzyme pro-drug therapy (ADEPT).
Francis RJ; Mather SJ; Chester K; Sharma SK; Bhatia J; Pedley RB; Waibel R; Green AJ; Begent RH
Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1090-6. PubMed ID: 15029458
[TBL] [Abstract][Full Text] [Related]
13. New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to the amide link.
Dowell RI; Springer CJ; Davies DH; Hadley EM; Burke PJ; Boyle FT; Melton RG; Connors TA; Blakey DC; Mauger AB
J Med Chem; 1996 Mar; 39(5):1100-5. PubMed ID: 8676345
[TBL] [Abstract][Full Text] [Related]
14. Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein.
Bhatia J; Sharma SK; Chester KA; Pedley RB; Boden RW; Read DA; Boxer GM; Michael NP; Begent RH
Int J Cancer; 2000 Feb; 85(4):571-7. PubMed ID: 10699932
[TBL] [Abstract][Full Text] [Related]
15. Antibody directed enzyme prodrug therapy (ADEPT): clinical report.
Bagshawe KD; Sharma SK; Springer CJ; Antoniw P; Boden JA; Rogers GT; Burke PJ; Melton RG; Sherwood RF
Dis Markers; 1991; 9(3-4):233-8. PubMed ID: 1813213
[TBL] [Abstract][Full Text] [Related]
16. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial.
Martin J; Stribbling SM; Poon GK; Begent RH; Napier M; Sharma SK; Springer CJ
Cancer Chemother Pharmacol; 1997; 40(3):189-201. PubMed ID: 9219501
[TBL] [Abstract][Full Text] [Related]
17. Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo.
Rogers GT; Burke PJ; Sharma SK; Koodie R; Boden JA
Br J Cancer; 1995 Dec; 72(6):1357-63. PubMed ID: 8519645
[TBL] [Abstract][Full Text] [Related]
18. Novel inhibitors of carboxypeptidase G2 (CPG2): potential use in antibody-directed enzyme prodrug therapy.
Khan TH; Eno-Amooquaye EA; Searle F; Browne PJ; Osborn HM; Burke PJ
J Med Chem; 1999 Mar; 42(6):951-6. PubMed ID: 10090777
[TBL] [Abstract][Full Text] [Related]
19. Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation.
Siemers NO; Kerr DE; Yarnold S; Stebbins MR; Vrudhula VM; Hellström I; Hellström KE; Senter PD
Bioconjug Chem; 1997; 8(4):510-9. PubMed ID: 9258449
[TBL] [Abstract][Full Text] [Related]
20. Antibody directed enzyme prodrug therapy (ADEPT): a three phase system.
Sharma SK; Bagshawe KD; Springer CJ; Burke PJ; Rogers GT; Boden JA; Antoniw P; Melton RG; Sherwood RF
Dis Markers; 1991; 9(3-4):225-31. PubMed ID: 1813212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
